检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《心电与循环》2014年第1期44-46,共3页Journal of Electrocardiology and Circulation
摘 要:目的观察缬沙坦联合胺碘酮对持续性心房颤动复律及复律后窦性心律维持率的影响。方法选择持续性心房颤动患者96例,随机分为两组,治疗组49例,给予缬沙坦及胺碘酮治疗,对照组47例给予安慰剂及胺碘酮治疗,随访1年,观察两组心房颤动转复率和转复后3、12个月时心房颤动复发率,以及转复时及转复后12个月左心房内径(LAD)、左心室射血分数(LVEF)变化。结果心房颤动转复率治疗组(87.8%)与对照组(85.1%)差异无统计学意义(P>0.05),心房颤动复发率转复后3个月及12个月治疗组(14.0%、23.2%)均小于对照组(32.5%、54.5%)(P<0.05或0 01),转律后12个月LAD治疗组[(44.3±0.65)mm)]较对照组[(46,9±0.54)mm]变小(P<0.05),LVEF治疗组[(56.8±8.64)%]较对照组[(52.3±9.08)%]升高(P<0.05)。结论缬沙坦联合胺碘酮治疗持续性心房颤动在减少心房颤动的复发率以及改善心功能方面优于单独使用胺碘酮。Objective To investigate the effect of Valsartan combined with Amiodarone on cardioversion of persistant atrial fibrillation (AF) and maintenance of sinus rhythm after cardioversion. Methods 96 patients with permanent AF were randomly divided into control group(n=47) and Valsartan group (n=49). The conversion rate of AF at one year and reoccur- rence of AF at 3 and 12 months after cardioversion were investigated. Left atrial dimension and left ventricular ejection frac- tion (LVEF) were measured at the moment of cardioversion and 12 months after cardioversion. Results The rate of AF cardioversion was not significant difference between two groups (87.8% vs 85.1%, P 〉0.05). The recurrence rate was sig- nificantly lower in Valsartan group than control group at 3 months (14.0% vs 32.5%, P〈0.05) and 12 months (23.2% vs 54.5%, P〈0.01 ). Left atrium significantly decreased (44.3 ± 0.65 mm vs 46.9 ± 0.54 mm, P〈0.05) and LVEF increased (56.8 ± 8.64% vs 52.3 ± 9.08%, P〈0.05) in Valsartan group at 12 months. Conclusion Valsartan with Amiodarone is su- perior to Amiodarone alone in maintaining sinus rhythm and improving heart function in the patients with permanent AF.
关 键 词:血管紧张素Ⅱ受体拮抗剂 缬沙坦 心房颤动 胺碘酮
分 类 号:R541.75[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.49